Educational Videos

UPDATE: Covid-19 and Immunocompromised Patients

May 12, 2022
The future of the pandemic? 2:47
Breakthrough COVID-19 3:34
Strategy for Outpatient Management of Immunocompromised Patients for COVID-19 4:43
The risk of severe COVID-19 in immunocompromised patients. 5:40
What’s in our toolbox for treatment of immunocompromised patients who get COVID-19? 6:39
Oral antivirals: paxlovid and molunpiravir 6:56
Monoclonal antibodies: bebtelovimab 7:48
What about preventing COVID-19 in immunocompromised patients? 8:26
Vaccination recommendation for immunocompromised patients. 8:41
Timing of booster with Rituximab. 9:27
Exciting development of Evusheld. 9:50
What we tell our patients now. 10:33
What it means to be fully vaccinated for immunocompromised patients. 11:04
Q&A: How long is the effectiveness of Evusheld 11:54
Q&A: What are the main considerations for the risk/benefit of determining if a patient should receive Evusheld? 13:28
Q&A: What are the three things that surprised you the most over the course of this COVID-19 pandemic? 16:47
Q&A: I’m a patient currently in remission and I’m concerned that I could go into relapse if I continue to get the boosters and additional doses of vaccine. Is this concern valid? 18:03
Q&A: What about the idea of holding Rituximab when getting the vaccine to help chances of building antibodies. 19:33
Q&A: Do you have an opinion about the efficacy of the vaccine waning over time how long does the second booster last? 21:20

The need for answers and information about the COVID-19 pandemic is especially for the relevant for patients who are immunocompromised. In this short webinar, Len Calabrese, MD, and his daughter, Casandra Calabrese, MD, give an update on the latest developments concerning antivirals, monoclonal antibody treatments, Euvsheld, vaccine efficacy, and boosters against variants.

Connect with us on social media!

Start Doing Your Bit to Help Others. Support Our Work.

Chip in with your donation

Our Mission

Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.

The Vasculitis Foundation is a registered 501 (c) (3) non-profit organization. All contributions are 100% tax-deductible.

Contact Us

Click here to send us an email!
Mail:
Vasculitis Foundation
PO Box 28660
Kansas City, MO 64188
1.816.436.8211 or 1.800.277.9474

Participate in Research

Learn how you can participate in clinical trials - National Institutes of Health

All Rights Reserved